articleNature BiotechnologyJul 1, 2012Closed access

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

PDPeter D. SenterELEric L. Sievers

Seagen (United States)

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

750
total citations
FWCI
27.49
Percentile
100%
References
68
Citations per year

Authors

2

Topics & keywords

Topics
Keywords
  • Brentuximab vedotin
  • Antibody-drug conjugate
  • Anaplastic large-cell lymphoma
  • Lymphoma
  • Hodgkin lymphoma
  • Medicine
  • Drug
  • Cancer research
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding